Department of Cardiovascular Medicine, Xiangya Hospital, Central South University, Changsha, China.
Eur Rev Med Pharmacol Sci. 2019 Jun;23(11):4940-4947. doi: 10.26355/eurrev_201906_18084.
Multiple microRNAs (miRNAs) are abnormally expressed in endothelial cells during the occurrence of coronary artery disease (CAD). Previous researches have demonstrated that miRNA-26a-5p participates in regulating the proliferation of vascular smooth muscle cells and angiogenesis. The aim of this study was to clarify the role of miRNA-26a-5p in regulating cellular performances of endothelial cells in the progression of CAD.
In vivo CAD model was successfully established by feeding high-fat diet in 8-week-old female ApoE/LDLR-/- mice. CAD mice were administered with miRNA-26a-5p NC or miRNA-26a-5p inhibitor, respectively. Meanwhile, coronary endothelial cells were isolated from CAD mice and normal controls. Relative levels of miRNA-26a-5p, the gene of phosphate and tension homology deleted on chromosome ten (PTEN) and vascular endothelial growth factor (VEGF) in CAD patients and coronary endothelial cells isolated from CAD mice were examined. The regulatory effect of miRNA-26a-5p on atherosclerosis-related genes in primary endothelial cells and HUVECs were detected as well. Moreover, the viability and apoptosis of primary endothelial cells with miRNA-26a-5p knockdown were assessed by cell counting kit-8 (CCK-8) assay and flow cytometry, respectively. Dual-luciferase reporter gene assay was conducted to identify the relationship between miRNA-26a-5p and PTEN. Furthermore, the regulatory role of miRNA-26a-5p in phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) pathway was examined in endothelial cells.
MiRNA-26a-5p and VEGF were significantly downregulated in CAD patients and primary endothelial cells isolated from CAD mice. However, PTEN was significantly upregulated. CAD mice administrated with miRNA-26a-5p inhibitor exhibited remarkably upregulated ET-1, TxA2, and ANG II, as well as downregulated eNOS and PGI2. Conversely, transfection of miRNA-26a-5p mimics in HUVECs obtained the opposite trends. PTEN was identified as the direct target gene of miRNA-26a-5p. Moreover, significantly reduced viability and enhanced apoptotic rate were observed in endothelial cells isolated from CAD mice administrated with miRNA-26a-5p inhibitor. In addition, the protein level of p-AKT in endothelial cells with miRNA-26a-5p knockdown was significantly down-regulated.
MiRNA-26a-5p influences the proliferative and apoptotic abilities of endothelial cells isolated from CAD mice by targeting PTEN to activate PI3K/AKT pathway.
在冠状动脉疾病(CAD)发生过程中,内皮细胞中多种 microRNAs(miRNAs)异常表达。先前的研究表明,miRNA-26a-5p 参与调节血管平滑肌细胞的增殖和血管生成。本研究旨在阐明 miRNA-26a-5p 在调节 CAD 进展过程中内皮细胞的细胞功能中的作用。
通过给 8 周龄雌性 ApoE/LDLR-/- 小鼠喂食高脂肪饮食,成功建立体内 CAD 模型。分别给予 miRNA-26a-5p NC 或 miRNA-26a-5p 抑制剂治疗 CAD 小鼠。同时,从 CAD 小鼠和正常对照中分离冠状动脉内皮细胞。检测 CAD 患者和从 CAD 小鼠中分离的冠状动脉内皮细胞中 miRNA-26a-5p、磷酸酶张力蛋白同源物缺失的第十号染色体(PTEN)和血管内皮生长因子(VEGF)的相对水平。检测 miRNA-26a-5p 对原代内皮细胞和 HUVECs 中动脉粥样硬化相关基因的调节作用。此外,通过细胞计数试剂盒-8(CCK-8)测定法和流式细胞术分别评估 miRNA-26a-5p 敲低对原代内皮细胞活力和凋亡的影响。双荧光素酶报告基因检测鉴定 miRNA-26a-5p 与 PTEN 之间的关系。此外,检测 miRNA-26a-5p 在内皮细胞中对磷脂酰肌醇 3-激酶(PI3K)/蛋白激酶 B(AKT)通路的调节作用。
miRNA-26a-5p 和 VEGF 在 CAD 患者和从 CAD 小鼠中分离的原代内皮细胞中显著下调,而 PTEN 显著上调。给予 miRNA-26a-5p 抑制剂的 CAD 小鼠表现出 ET-1、TxA2 和 ANG II 的显著上调,以及 eNOS 和 PGI2 的下调。相反,转染 miRNA-26a-5p 模拟物在 HUVECs 中获得了相反的趋势。PTEN 被鉴定为 miRNA-26a-5p 的直接靶基因。此外,给予 miRNA-26a-5p 抑制剂的 CAD 小鼠分离的内皮细胞活力显著降低,凋亡率显著升高。此外,miRNA-26a-5p 敲低的内皮细胞中 AKT 的磷酸化水平显著降低。
miRNA-26a-5p 通过靶向 PTEN 激活 PI3K/AKT 通路,影响从 CAD 小鼠中分离的内皮细胞的增殖和凋亡能力。